详情页 - 河北医科大学第四医院机构库

资源类型：

文章类型：

作者：

Qu, Yuan-Yuan[1,2,3,4,5,6,7,8,9,10] * ; Guo, Hongqian[1,2,3,4,5,6,7,8,9,10] ; Luo, Hong[1,2,3,4,5,6,7,8,9,10] ; Zou, Qing[1,2,3,4,5,6,7,8,9,10] ; Xing, Ninazeng[1,2,3,4,5,6,7,8,9,10] ; Sun, Zhongquan[1,2,3,4,5,6,7,8,9,10] ; Zhang, Xuepei[1,2,3,4,5,6,7,8,9,10] ; Xia, Shujie[1,2,3,4,5,6,7,8,9,10] ; He, Chaohong[1,2,3,4,5,6,7,8,9,10] ; Zhang, Hailiang[1,2,3,4,5,6,7,8,9,10] ; Cai, Jinling[1,2,3,4,5,6,7,8,9,10] ; Zhang, Xiao[1,2,3,4,5,6,7,8,9,10] ; Wang, Quanren[1,2,3,4,5,6,7,8,9,10] ; Ye, Dingwei[1,2,3,4,5,6,7,8,9,10] ;

机构： [1]Fudan University Shanghai Cancer Center, Shanghai, China [2]Nanjing Drum Tower Hospital, Nanjing, China [3]Chongqing Cancer Hospital, Chongqing, China [4]Jiangsu Cancer Hospital, Jiangsu, China [5]Jiangsu Cancer Hospital, Nanjing, China [6]Shanghai Huadong Hospital, Shanghai, China [7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [8]Shanghai General Hospital, Shanghai, China [9]Cancer Hospital of Henan Province, Zhengzhou, China [10]Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China

出处：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Fudan University Shanghai Cancer Center, Shanghai, China [2]Nanjing Drum Tower Hospital, Nanjing, China [3]Chongqing Cancer Hospital, Chongqing, China [4]Jiangsu Cancer Hospital, Jiangsu, China [5]Jiangsu Cancer Hospital, Nanjing, China [6]Shanghai Huadong Hospital, Shanghai, China [7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [8]Shanghai General Hospital, Shanghai, China [9]Cancer Hospital of Henan Province, Zhengzhou, China [10]Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.

文献详情